ARCHIVES

FDA Advisors Give Dox-SL Conditional Approval; Ok Zoladex

This article is from The Cancer Letter archive.

Vol. 21 No. 08 | February 24, 1995

Download PDF Visit The Full Archive

Related Articles

Increase In DCCR Grants May Not Be Possible Without Decreasing Quality, Committee Told

July 28, 1978

Gramm-Rudman Cut Facing NCI Could Take $85 Million

October 20, 1989

Fox Chase Cancer Center Board Selects Michael Seiden of Dana-Farber/Harvard As New President.

March 23, 2007

Richard Bloch, advocate for patient information services, dead at 78.

July 30, 2004

Health Reform Bill Contains Unpleasant Surprises For Drug Manufacturers

November 5, 1993

ACCC Enthusiastically Support New Effort Or Clinical Research

April 3, 1981